FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896652675> ?p ?o ?g. }

• W2896652675 endingPage "1214" @default.
• W2896652675 startingPage "1208" @default.
• W2896652675 abstract "Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. placebo in patients with unresectable pancreatic cancer was determined. This was a two-part, multinational study: phase 1b was a non-randomised, open-label, multicentre, and dose-escalation study; phase 2 was a randomised, placebo- and Bayesian-augmented controlled, double-blind study in patients with locally advanced or metastatic pancreatic adenocarcinoma considered candidates for first-line chemotherapy with gemcitabine. Patients were randomised 2:1 to galunisertib–gemcitabine (N = 104) or placebo-gemcitabine (N = 52). Gemcitabine dose was 1000 mg/m2 QW. Primary endpoints for phases 1b and 2, respectively, were phase 2 dose and overall survival. Secondary objectives included tolerability and biomarkers. Dose-escalation suggested a 300-mg/day dose. Primary objective was met: median survival times were 8.9 and 7.1 months for galunisertib and placebo, respectively (hazard ratio [HR] = 0.79 [95% credible interval: 0.59–1.09] and posterior probability HR < 1 = 0.93). Lower baseline biomarkers macrophage inflammatory protein-1-alpha and interferon-gamma-induced protein 10 were associated with galunisertib benefit. Galunisertib–gemcitabine combination improved overall survival vs. gemcitabine in patients with unresectable pancreatic cancer, with minimal added toxicity. Future exploration of galunisertib in pancreatic cancer is ongoing in combination with durvalumab." @default.
• W2896652675 created "2018-10-26" @default.
• W2896652675 creator A5005128603 @default.
• W2896652675 creator A5006585898 @default.
• W2896652675 creator A5015190461 @default.
• W2896652675 creator A5020397401 @default.
• W2896652675 creator A5021535454 @default.
• W2896652675 creator A5023325144 @default.
• W2896652675 creator A5024665791 @default.
• W2896652675 creator A5031770911 @default.
• W2896652675 creator A5033549340 @default.
• W2896652675 creator A5033800692 @default.
• W2896652675 creator A5034922000 @default.
• W2896652675 creator A5035341984 @default.
• W2896652675 creator A5041950187 @default.
• W2896652675 creator A5049680516 @default.
• W2896652675 creator A5056028552 @default.
• W2896652675 creator A5064692327 @default.
• W2896652675 creator A5082191671 @default.
• W2896652675 date "2018-10-15" @default.
• W2896652675 modified "2023-10-12" @default.
• W2896652675 title "Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer" @default.
• W2896652675 cites W1700691315 @default.
• W2896652675 cites W1931508686 @default.
• W2896652675 cites W1968812902 @default.
• W2896652675 cites W1974423029 @default.
• W2896652675 cites W2064494174 @default.
• W2896652675 cites W2066230562 @default.
• W2896652675 cites W2082636073 @default.
• W2896652675 cites W2125061065 @default.
• W2896652675 cites W2136280424 @default.
• W2896652675 cites W2151253787 @default.
• W2896652675 cites W2163707617 @default.
• W2896652675 cites W2165480504 @default.
• W2896652675 cites W2171847801 @default.
• W2896652675 cites W2235523093 @default.
• W2896652675 cites W2285093314 @default.
• W2896652675 cites W2318215800 @default.
• W2896652675 cites W2415398754 @default.
• W2896652675 cites W2608051959 @default.
• W2896652675 doi "https://doi.org/10.1038/s41416-018-0246-z" @default.
• W2896652675 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6251034" @default.
• W2896652675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30318515" @default.
• W2896652675 hasPublicationYear "2018" @default.
• W2896652675 type Work @default.
• W2896652675 sameAs 2896652675 @default.
• W2896652675 citedByCount "176" @default.
• W2896652675 countsByYear W28966526752019 @default.
• W2896652675 countsByYear W28966526752020 @default.
• W2896652675 countsByYear W28966526752021 @default.
• W2896652675 countsByYear W28966526752022 @default.
• W2896652675 countsByYear W28966526752023 @default.
• W2896652675 crossrefType "journal-article" @default.
• W2896652675 hasAuthorship W2896652675A5005128603 @default.
• W2896652675 hasAuthorship W2896652675A5006585898 @default.
• W2896652675 hasAuthorship W2896652675A5015190461 @default.
• W2896652675 hasAuthorship W2896652675A5020397401 @default.
• W2896652675 hasAuthorship W2896652675A5021535454 @default.
• W2896652675 hasAuthorship W2896652675A5023325144 @default.
• W2896652675 hasAuthorship W2896652675A5024665791 @default.
• W2896652675 hasAuthorship W2896652675A5031770911 @default.
• W2896652675 hasAuthorship W2896652675A5033549340 @default.
• W2896652675 hasAuthorship W2896652675A5033800692 @default.
• W2896652675 hasAuthorship W2896652675A5034922000 @default.
• W2896652675 hasAuthorship W2896652675A5035341984 @default.
• W2896652675 hasAuthorship W2896652675A5041950187 @default.
• W2896652675 hasAuthorship W2896652675A5049680516 @default.
• W2896652675 hasAuthorship W2896652675A5056028552 @default.
• W2896652675 hasAuthorship W2896652675A5064692327 @default.
• W2896652675 hasAuthorship W2896652675A5082191671 @default.
• W2896652675 hasBestOaLocation W28966526751 @default.
• W2896652675 hasConcept C121608353 @default.
• W2896652675 hasConcept C126322002 @default.
• W2896652675 hasConcept C142724271 @default.
• W2896652675 hasConcept C143998085 @default.
• W2896652675 hasConcept C197934379 @default.
• W2896652675 hasConcept C203092338 @default.
• W2896652675 hasConcept C204787440 @default.
• W2896652675 hasConcept C207103383 @default.
• W2896652675 hasConcept C27081682 @default.
• W2896652675 hasConcept C2778375690 @default.
• W2896652675 hasConcept C2780210213 @default.
• W2896652675 hasConcept C2780258809 @default.
• W2896652675 hasConcept C44249647 @default.
• W2896652675 hasConcept C535046627 @default.
• W2896652675 hasConcept C71924100 @default.
• W2896652675 hasConcept C90924648 @default.
• W2896652675 hasConceptScore W2896652675C121608353 @default.
• W2896652675 hasConceptScore W2896652675C126322002 @default.
• W2896652675 hasConceptScore W2896652675C142724271 @default.
• W2896652675 hasConceptScore W2896652675C143998085 @default.
• W2896652675 hasConceptScore W2896652675C197934379 @default.
• W2896652675 hasConceptScore W2896652675C203092338 @default.
• W2896652675 hasConceptScore W2896652675C204787440 @default.
• W2896652675 hasConceptScore W2896652675C207103383 @default.
• W2896652675 hasConceptScore W2896652675C27081682 @default.
• W2896652675 hasConceptScore W2896652675C2778375690 @default.
• W2896652675 hasConceptScore W2896652675C2780210213 @default.

• next